B2B Meetings

ESPCI Laboratoire de Biochimie

Organisation type Research
Organisation size 250+

Participant Details


Dr Elodie Brient-Litzler

Project Manager

Morning Sessions - Nov, 13th

  • Company or project Pitch session

Afternoon Sessions - Nov, 13th

  • Networking lunch
  • Partnering meetings

Organisation Details

The Laboratory of Biochemistry (evaluated A+ by AERES) was created at the Ecole Supérieure de Phyique Chimie Industrielle de la ville de Paris in September 2012 and is directed by Prof. Andrew Griffiths, one of the key figures in the development of phage-display for the selection of human antibodies for therapy. Today, the research activities of LBC are based around droplet-based microfluidics applied to fundamental project on evolution and applied project in the field of drug discovery, diagnostics, vaccines and biomarkers. Andrew Griffiths is co-founder of Raindance Technologies and HiFiBio, is coordinator and deputy coordinator, respectively, of two Investissements d’Avenir projects, DigiDiag and Medalis, and holds an ERC Advanced Grant. More information can be found at

HiFiBiO SAS is a spin-off of LBC and was incorporated in August 2013 in Paris. The company commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development. Their scientific founders have deep, world-leading expertise in microfluidics (Prs Andrew Griffiths and Jérôme Bibette, ESPCI; Pr David Weitz, Harvard), epigenetics (Pr Bradley Bernstein, Harvard), next-generation sequencing and bioinformatics (Dr Robert Nicol, Broad Institute). Their seasoned executive team has a strong track record of success in building high value life science companies based on university-licensed technologies. HiFiBiO is a 2013 laureate in the “Création Développement” competition of OSEO - BPIfrance. More information can be found at


Areas of Activity

Field of application
  • Other
  • Immunology
Activity sector
  • Biomarker discovery
  • Biologics development (Recombinant proteins, antibodies, DNA/RNA products)
  • Diagnostics test development

Cooperation Profiles

Offer: Quantitative, high Troughput single-cell ChIP and RNA-seq technologies for epigenetic biomarker discovery and immune system profiling



The Laboratory of Biochemistry at ESPCI and its spin-off company HiFiBiO are developing a new approach for profiling cell populations based on quantitative, high throughput, single-cell ChIP and RNA-seq technologies.  Our approach is uniquely suited to dissect complex biological heterogeneity and reveal those specific cells of unique diagnostic or therapeutic value.

We have identified two high value applications for this platform capability.  Epigenetic drug discovery and development is presented hindered by an inability to identify cells with aberrant epigenomes and measure the affects of epigenetically-targeted drugs.  Our single cell ChIP-seq and RNA-seq capability allows for the cell-by-cell segmentation of complex tissues like tumors to reveal those subtypes that are, for example, chemo-resistant or responsible for tumorgenesis.  Current analytic methods are woefully inadequate as they are only capable of providing averaged molecular information on a tissue and therefore incapable of detecting disease-significant cell subpopulations. 

Discovery of therapeutic or diagnostic antibodies, the second application of this technology, is currently hindered by an inability to identify and extract correlated phenotype-genotype information from a repertoire of antibody secreting cells (ASC).  Our approach alleviates that restriction and enables cell-by-cell antibody phenotype quantification, sorting and sequencing of antibody cognate heavy/light chain pairs that links antibody phenotype with genotype.  We are presently validating both applications through partnerships with pharmaceutical and biotechnology companies and welcome enquiries.




We combine advances in droplet microfluidic, DNA barcoding and bioinformatic technologies to enable quantitative ChIP-seq and RNA-seq analysis of single cells.  Single cells are co-encapsulated in micrometer-sized drops and analyzed to identify specific phenotypes of interest.  The individual drops are sorted according to phenotype and merged with a drop containing a unique oligonucleotide barcode identifier ligated to the specific nucleic acids of interest in the encapsulated cell. The sorted populations are sequenced and analyzed with a dedicated bioinformatics pipeline.  For our epigenetics application, the barcodes are ligated to nucleosomal DNA after MNase digestion in droplets and sequence maps created showing relative abundance of specific histone modifications across the genome. The antibody application uses a similar approach except the mRNA encoding the heavy/light chain sequences is specifically captured and reverse transcribed to create barcoded cDNA ready for sequencing.  In each application, the sequence data is processed by a dedicated and proprietary bioinformatics protocol and system. 



The advantages of our technology in epigenetics and antibody therapeutics development are multi-fold.  For antibody development, it will enable, for the first time, the ability to completely and comprehensively profile the antibody repertoire produced in response to an antigen challenge. Not only will this profoundly change our understanding of immunology but the ability to retrieve cognate pair sequences correlated with antibody phenotype will greater decrease development pipelines by allowing selection of clinically-relevant antibodies. Furthermore, this same approach has clear diagnostic value by enabling the ability to profile and categorize immune system response based on antibody phenotype and genotype.  We believe this will have a profound impact on the ability to target antibody medicines in a personalized and precision way.

Second, application to epigenetics will enable to retrieve single cell information from heterogeneous cell populations, providing insights into epigenetic processes currently buried in the background noise of the conventional ChIP-seq process.  We anticipate applications in new epigenetic target discovery and validation, high throughput screening and diagnostic epigenetic biomarker discovery and validation.   



ChIP-seq: POC delivered

RNA-Seq: under development, separate technological modules demonstrated


TARGET PARTNER SOUGHT: We are looking for partners interested in having early access to this technology for biomarker discovery or therapeutic development. Custom technological developments (target genes, target cell subsets…) can be envisioned in the frame of a collaborative research program with HiFiBiO or between the LBC, HiFiBiO and the partner.

Cooperation Type:

  • Offered: Research cooperation